Dual-targeted exosome nanoplatform co-delivering doxorubicin and Fuzi Lizhong Tang bioactives for synergistic DLBCL therapy and chemotherapy-induced diarrhea management
Colloids and Surfaces B: Biointerfaces · 2026
DOI: 10.1016/j.colsurfb.2025.115271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colloids and Surfaces B: Biointerfaces, 2026. Verfasst von Lin Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First People's Hospital of Yunan Province, Kunming, Yunnan 650032, China; The Affiliated Hospital of Kunming University of Science and Technology…. Hauptthemen laut MEDLINE: Exosomes, Doxorubicin, Nanomedicine, Diarrhea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The management of chemotherapy-induced diarrhea (CID) in diffuse large B-cell lymphoma (DLBCL) requires strategies that concurrently address intestinal protection and tumor-targeted therapy. In this study, we developed a multifunctional nano-delivery system based on natural exosomes to co-encapsulate doxorubicin (DOX) and bioactive components derived from the traditional Chinese medicine Fuzi Lizhong Tang (gingerol and atractylenolide), aiming to synchronize DLBCL-targeted chemotherapy with CID alleviation. Exosomes (TEX) isolated from the human DLBCL cell line OCI-Ly3 were loaded with DOX and the herbal components via electroporation, yielding TEX@DOX-Herb. The tumor-homing capability, mediated by surface CD19/CD20 proteins, enabled precise DOX delivery, resulting in superior tumor growth inhibition (∼90 % vs. ∼70 % for DOX alone) and significantly prolonged survival (overall survival: 38 days vs. 30 days with DOX alone) in xenograft models. Concurrently, the exosomes exhibited intestinal tropism, facilitating the localized release of gingerol and atractylenolide. This led to a marked reduction in severe diarrhea incidence (∼40 %) and restored intestinal barrier integrity, as evidenced by suppressed NF-κB-driven inflammation and upregulated tight junction proteins. Furthermore, TEX@DOX-Herb showed negligible systemic toxicity. These findings highlight the dual-targeting potential of tumor-derived exosomes as a biocompatible platform to synergize traditional herbal medicine with modern chemotherapy, offering a promising therapeutic paradigm for DLBCL patients to mitigate chemotherapy complications while optimizing oncologic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First People's Hospital of Yunan Province, Kunming, Yunnan 650032, China; The Affiliated Hospital of Kunming University of Science and Technology, China; Yunnan Province Clinical Research Center for Hematologic Dise…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, L., Hu, R., Zhang, J., & Zhang, H. (2026). Dual-targeted exosome nanoplatform co-delivering doxorubicin and Fuzi Lizhong Tang bioactives for synergistic DLBCL therapy and chemotherapy-induced diarrhea management. Colloids and Surfaces B: Biointerfaces. https://doi.org/10.1016/j.colsurfb.2025.115271
Vancouver
Zhang L, Hu R, Zhang J, Zhang H. Dual-targeted exosome nanoplatform co-delivering doxorubicin and Fuzi Lizhong Tang bioactives for synergistic DLBCL therapy and chemotherapy-induced diarrhea management. Colloids and Surfaces B: Biointerfaces. 2026. doi:10.1016/j.colsurfb.2025.115271
BibTeX
@article{Zhang2026,
author = {Zhang, Lin and Hu, Rui and Zhang, Jinping and Zhang, Haixi},
title = {Dual-targeted exosome nanoplatform co-delivering doxorubicin and Fuzi Lizhong Tang bioactives for synergistic DLBCL therapy and chemotherapy-induced diarrhea management},
journal = {Colloids and Surfaces B: Biointerfaces},
year = {2026},
doi = {10.1016/j.colsurfb.2025.115271}
}
EUVIMED